Release Summary

Acetylon announces oral presentation at ASH on data demonstrating the utility of selective HDAC1,2 inhibition by ACY-957 to induce gamma globin for sickle cell disease and beta-thalassemia.

Acetylon Pharmaceuticals, Inc.